| Vol. 6.28 – 5 August, 2022 |
| |
|
|
| Scientists showed that non-alcoholic fatty liver disease and steatohepatitis were characterized by iron-deficient hepatocytes and iron overload in hepatic stellate cells. [Cell Metabolism] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators dissected the role of Mettl3-mediated N6-methyladenosine (m6A) modification in postnatal liver development and homeostasis. [Nature Communications] |
|
|
|
| The authors reported that hepatic Wilms’ tumor 1-associating protein (WTAP) was a key integrative regulator of ectopic lipid accumulation and inflammation during NASH progression. [Nature Communications] |
|
|
|
| Investigators reported that a newly developed, orally active small molecule inhibitor targeting threonine tyrosine kinase (TTK) effectively suppressed HCC growth and induced highly aneuploid HCC cells, DNA damage, and micronuclei formation. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors found that the hepatic stellate cell (HSC)-specific knockout of m6A methyltransferase Mettl3 suppressed HSC activation and significantly alleviated liver fibrosis. [Molecular Therapy] |
|
|
|
| Hepatic stellate cells (HSCs) were isolated, and the relationship between S100A16 expression and HSCs activation was studied. [Metabolism Clinical and Experimental] |
|
|
|
| The role of nucleoredoxin on HCC proliferation was determined by CCK-8, EdU and colony formation assays in vitro and subcutaneous tumor formation model in vivo. [Cell Death & Disease] |
|
|
|
| Researchers used human induced pluripotent stem cells (iPSCs) generated from normal and genetically obese subjects and differentiated them into hepatocytes in cell culture. They showed that hepatocytes from obese iPSCs stored more lipids and showed increased cell death than normal iPSCs. [Cell Death & Disease] |
|
|
|
| Scientists used a liver-specific conditional knockout approach to delete Pten in combination with deletion of E2f7/8, known key inducers of polyploidization. [Liver International] |
|
|
|
| Overexpression of miR-182-5p failed to promote proliferation in hepatocytes, but stimulated proliferation when hepatocytes were cocultured with stellate cells. [Communications Biology] |
|
|
|
| The authors investigated the underlying mechanism of the long non-coding RNA CERS6-AS1 in HCC progression. [Cell Death Discovery] |
|
|
|
| Hypoxia substantially increased Hormad1 expression in primary mouse hepatocytes. Despite the presence of three putative hypoxia response elements within the mouse Hormad1 gene, the Hif-1alpha siRNA only slightly decreased hypoxia-induced Hormad1 mRNA expression. [Scientific Reports] |
|
|
|
| Researchers investigated individual cytokine and growth factor profiles in post-hepatectomy regeneration. Primary hepatocytes isolated from patient tissue samples were stimulated and their proliferation was analysed through DNA content assay. [Scientific Reports] |
|
|
|
|
|
| Scientists focus on studies involving hepatocyte growth factor (HGF)/mesenchymal stem cells (MSCs) both in vitro and in vivo. The characteristics of HGF/MSCs are summarized, and the mechanisms of their improved therapeutic efficacy are analyzed. [Journal of Cellular and Molecular Medicine] |
|
|
|
| Investigators focus on the role of different deubiquitinases on mitophagy and their contribution to nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcohol-related liver disease, and especially HCC. [Journal of Cellular Biochemistry] |
|
|
|
| The authors shed light on various established 3D culture models of HCC and their role in the investigation of tumour-tumor microenvironment interactions and HCC-related therapeutic resistance. [Cancer Cell International] |
|
|
|
|
| CymaBay Therapeutics, Inc. announced the completion of enrollment for RESPONSE, a global Phase III study evaluating seladelpar for patients with Primary Biliary Cholangitis. [CymaBay Therapeutics, Inc.] |
|
|
|
|
| December 3-7, 2022 Washington, DC, United States |
|
|
|
|
|
| University of Kansas Medical Center – Kansas City, Kansas, United States |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Mayo Clinic – Scottsdale, Arizona, United States |
|
|
|
| University of North Carolina at Greensboro – Kannapolis, North Carolina, United States |
|
|
|
| Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
|